Literature DB >> 21773951

Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Elizabeth M Oliva1, Natalya C Maisel, Adam J Gordon, Alex H S Harris.   

Abstract

Substance use disorders are highly prevalent, debilitating conditions for which effective pharmacotherapies exist with a broad evidence base, yet pharmacotherapy for the treatment of addiction disorders is underutilized. The goals of this review are to describe the barriers that may contribute to poor adoption and utilization of pharmacotherapy for alcohol and opioid dependence at the system, provider, and patient level and to discuss ways to overcome those barriers. Multifaceted efforts directed at all three levels may be needed to speed pharmacotherapy adoption. More research is needed to help us better understand barriers from patients' perspectives. Strategies to promote adoption of pharmacotherapy for addiction disorders should be modified to fit the needs of the practice, system, and individual patients. Pharmacotherapy is a valuable tool in the clinical armamentarium of addiction treatment; thus, overcoming barriers to implementation may improve clinical and social outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773951      PMCID: PMC4403628          DOI: 10.1007/s11920-011-0222-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  64 in total

1.  Office-based treatment for opioid dependence: reaching new patient populations.

Authors:  D A Fiellin; R A Rosenheck; T R Kosten
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

2.  Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians.

Authors:  Heino Stöver
Journal:  Eur Addict Res       Date:  2010-10-26       Impact factor: 3.015

3.  The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.

Authors:  James L Snyder; Thomas G Bowers
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

4.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

5.  Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.

Authors:  John P Fitzgerald; Dennis McCarty
Journal:  Psychol Serv       Date:  2009-02-01

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 7.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

8.  Counselor attitudes toward pharmacotherapies for alcohol dependence.

Authors:  Amanda J Abraham; Lori J Ducharme; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

Review 9.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  61 in total

Review 1.  Neuromodulation interventions for addictive disorders: challenges, promise, and roadmap for future research.

Authors:  Primavera A Spagnolo; David Goldman
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

2.  Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.

Authors:  Katherine J Karriker-Jaffe; Jianguang Ji; Jan Sundquist; Kenneth S Kendler; Kristina Sundquist
Journal:  Addiction       Date:  2017-05-16       Impact factor: 6.526

3.  Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans.

Authors:  Kevin L Kraemer; Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Adam J Gordon; Jonathan Robbins; Susan Zickmund; Kendall Bryant; P Todd Korthuis
Journal:  J Subst Abuse Treat       Date:  2019-05-07

4.  Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.

Authors:  Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris
Journal:  J Gen Intern Med       Date:  2017-10-30       Impact factor: 5.128

5.  Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.

Authors:  Andrea K Finlay; Laura S Ellerbe; Jessie J Wong; Christine Timko; Anna D Rubinsky; Shalini Gupta; Thomas R Bowe; Jennifer L Burden; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2017-03-10

6.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

Review 7.  Pharmacogenetics of alcohol use disorder treatments: an update.

Authors:  Emily E Hartwell; Henry R Kranzler
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-11       Impact factor: 4.481

8.  The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

Authors:  Sharon Reif; Mary F Brolin; Maureen T Stewart; Thomas J Fuchs; Elizabeth Speaker; Shayna B Mazel
Journal:  J Subst Abuse Treat       Date:  2019-07-19

9.  Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.

Authors:  Mandy D Owens; George N Ioannou; Judith L Tsui; E Jennifer Edelman; Preston A Greene; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2018-05-08       Impact factor: 4.492

10.  Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen
Journal:  J Subst Abuse Treat       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.